Average cost of multi drug-resistant tuberculosis treatment in Zambia
Zambia: Average cost of multi drug-resistant tuberculosis treatment was 600 constant 2022 US$ in 2024. ▼ Falling
Average cost of multi drug-resistant tuberculosis treatment in Zambia, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of multi drug-resistant tuberculosis treatment in Zambia is 600 constant 2022 US$, measured in 2024. That is the lowest value across all 8 years on record.
Compared with earlier readings it is down 73.5% on the previous year and down 89.7% over ten years.
That places Zambia 72nd out of 92 countries with data for 2024, putting it in the bottom quarter.
Average cost of multi drug-resistant tuberculosis treatment in Zambia, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 5,822 constant 2022 US$ | — |
| 2018 | 5,822 constant 2022 US$ | +0.0% |
| 2019 | 5,822 constant 2022 US$ | +0.0% |
| 2020 | 5,822 constant 2022 US$ | +0.0% |
| 2021 | 5,822 constant 2022 US$ | +0.0% |
| 2022 | 2,268 constant 2022 US$ | -61.0% |
| 2023 | 2,268 constant 2022 US$ | +0.0% |
| 2024 | 600 constant 2022 US$ | -73.5% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 5,822 constant 2022 US$ | 5,822 constant 2022 US$ | 5,822 constant 2022 US$ | 3 |
| 2020s | 3,356 constant 2022 US$ | 600 constant 2022 US$ | 5,822 constant 2022 US$ | 5 |
Countries ranked near Zambia
- 69 South Sudan 682 constant 2022 US$ compare
- 70 Venezuela, Bolivarian Republic of 674 constant 2022 US$ compare
- 71 Guinea 616 constant 2022 US$ compare
- 73 El Salvador 574 constant 2022 US$ compare
- 74 Panama 572 constant 2022 US$ compare
- 75 Peru 570 constant 2022 US$ compare
More health data for Zambia
- Un projection of annual infant deaths, annual growth rate -1.09 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7971 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 809.3 deaths per 1,000 people (2090)
- Number of infants who die before age 1 8,894 deaths (2100)
- Population ages 75-79, female, annual growth rate 5.38 % change on previous year (2025)
- Population ages 75-79, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 75-79, female, per capita 0.0018 units per person (2025)
- Population ages 75-79, male, annual growth rate 4.29 % change on previous year (2025)
- Population ages 75-79, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 75-79, male, per capita 0.0011 units per person (2025)
Frequently asked questions
- What is average cost of multi drug-resistant tuberculosis treatment in Zambia?
- Average cost of multi drug-resistant tuberculosis treatment in Zambia was 600 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of multi drug-resistant tuberculosis treatment recorded in Zambia?
- The highest recorded value was 5,822 constant 2022 US$ in 2017.
- What is the lowest average cost of multi drug-resistant tuberculosis treatment recorded in Zambia?
- The lowest recorded value was 600 constant 2022 US$ in 2024.
- How does Zambia rank for average cost of multi drug-resistant tuberculosis treatment?
- Zambia ranks 72nd out of 92 countries with data for 2024.
- Is average cost of multi drug-resistant tuberculosis treatment rising or falling in Zambia?
- Over the last ten years it is down 89.7%. The long-run trend across the full record is falling.
- Where does this Zambia data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of multi drug-resistant tuberculosis treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.